Videos

Cohen cites past failures with risk-based hepatitis B vaccination and voices concerns about the CDC APIC vote for individual-based decision-making.

Next-generation TIC-2 inhibitors show remarkable selectivity, enhancing efficacy while minimizing side effects, offering insights into immune system safety.

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

Explore the distinct role of TIC-2 in psoriasis and how selective inhibition offers targeted treatment advantages over traditional JAK inhibitors.

This December 4 episode of Skin of Color Savvy highlights takeaways from the SOCS Virtual Media Day.

Recent advancements in HAE treatments offer hope, but experts stress the need for more pediatric options and diverse therapies.

Bilen discusses the COLLIGO-HCM trial, investigating the real-world efficacy of mavacamten monotherapy for patients with obstructive HCM.

Hanania explains how IL-33 inhibitors including itepekimab and astegolimab may uniquely benefit COPD exacerbation.

Gibson discusses the promising improvements to the composite primary endpoint of mortality, stroke, and recurrent MI as a result of zalunfiban treatment.

Barr discusses the means to encourage systemic adoption of low dose CT scans to help curb the deadliest cancer in the US.

Sorajja discusses the results of this groundbreaking trial investigating a new implant for patients with severe mitral annular calcification.

The phase 2 study of ALXN2050 in IgAN did not meet its proteinuria endpoint, with emerging safety concerns and early termination.

Rosovsky discusses the revolutionary new therapy’s potential to revolutionize the field of pulmonary embolism treatment.

O’Donoghue discusses the results of this analysis of the FOURIER trial, highlighting that no limit was found for lowered LDL-C improving MACE risk.

Yan discusses the reversion of 50-year trends in mortality and the steps needed to reduce these rates back to pre-pandemic levels.

O’Donoghue discusses the results of the recent OCEAN(a)-DOSE trial and addresses the implications for Lp(a)-lowering therapies moving forward.

Kirkorian speaks in this interview about her sessions at SDPA Fall on genetic disorders in pediatric dermatology patients.

Halpin reviews the state of triple therapy inhaler prescribing strategies in the era of new biologic options.

Soong discussed the role of allergist's in atopic dermatitis care at a recent HCPLive clinical forum.

Explore the long-term safety and efficacy of JAK inhibitors in atopic dermatitis, enhancing patient care and clinician confidence.

Healthcare providers discuss the importance of effective communication when switching patients from biologics to JAK inhibitors.

Clinicians discuss the importance of patient-centered treatment decisions and the need to address therapeutic inertia in managing chronic conditions.

Explore the evolving landscape of atopic dermatitis treatment, focusing on advanced therapies and long-term patient management strategies.

Healthcare professionals explore effective questioning techniques to uncover deeper emotional and physical impacts of skin pain in patients.

This video explores skin pain as a key symptom of atopic dermatitis and reviews clinical trial data with JAK inhibitors.

Experts discuss the future of psoriasis treatment, highlighting the potential of oral therapies to enhance patient adherence and quality of life.

Explore the complexities of psoriasis treatment, including advanced therapies, mechanisms of action, and the potential of molecular testing for personalized care.

CAVT effectively reduced right-to-left ventricular diameter ratio within 48 hours, with earlier vital sign normalizing and similar adverse event rates to AC.